Notably, treatment of NOD mice at a late preclinical T1D stage with AAViP-IL2 results in the expansion of islet-resident Foxp3+Treg, suppression of β cell-specific Teff, and prevention of diabetes onset (72–74). The gene discussed is FOXP3; the disease is diabetes mellitus.